Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that PDGFRB rearrangements status confers therapeutic sensitivity to Imatinib in patients with Myeloproliferative Neoplasm.

The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.

This statement is based on a regulatory approval from the European Medicines Agency:

Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

Citation

Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2001-11-07	European Medicines Agency	Indication received approval from the European Commission.